A UCLH patient is the first person in the UK to receive a new investigational drug being tested for a disorder caused by genetic mutations, called classic congenital adrenal hyperplasia.
UCLH has recruited the first UK participant to a trial of a new immunotherapy drug for patients with advanced solid cancers who no longer respond to existing treatments.
An international clinical trial testing a novel cancer immunotherapy which may prevent skin cancer from recurring has recruited its first patients at UCLH.
UCLH’s trial of the world’s first ‘gene silencing’ drug for Alzheimer’s disease has progressed into a larger and later stage trial, after promising early results.
A world-class research team at UCLH and UCL has been awarded £3.76m to carry out a countrywide trial to identify accurate and quick blood tests that can diagnose dementia.
The UCLH BRC and CRF have published an Equality, Diversity and Inclusion (EDI) strategy to ensure equitable opportunity for all in research, regardless of background.
A new study supported by the NIHR BRC at UCLH has demonstrated the potential of an AI tool to predict the health trajectory of patients by forecasting future disorders, symptoms, medications and procedures.
Researchers at the BRC and the Francis Crick Institute have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to evolve.
Professor Karl Peggs has been appointed as UCLH director of research and director of the National Institute for Health and Care Research UCLH Biomedical Research Centre.
A cancer treatment that is currently available to only a limited number of UK patients is to be tested at UCLH in a countrywide clinical trial to see if it causes fewer long-term side effects than standard radiotherapy.
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
